Enantia's cocrystallization technology endorsed by global partnership
An innovative cocrystal, obtained by Enantia in collaboration with Esteve R&D, is part of the global partnership recently announced by Esteve and Mundipharma-Purdue.
Enantia —a technology based spin-off of the University of Barcelona (UB), headquartered at the Barcelona Science Park (PCB)— develops technologies and provides services in the fields of medicinal chemistry, process chemistry and solid forms. The company has played a fundamental role in obtaining a single new cocrystal entity composed of two active substances used in pain management.
Enantia received the Senén Vilaró Prize for the best innovative company in 2011. Joan Feixas is the chief executive officer of the company, and Llorenç Rafecas is its technical director.
An innovative cocrystal, obtained by Enantia in collaboration with Esteve R&D, is part of the global partnership recently announced by Esteve and Mundipharma-Purdue.
Enantia —a technology based spin-off of the University of Barcelona (UB), headquartered at the Barcelona Science Park (PCB)— develops technologies and provides services in the fields of medicinal chemistry, process chemistry and solid forms. The company has played a fundamental role in obtaining a single new cocrystal entity composed of two active substances used in pain management.
Enantia received the Senén Vilaró Prize for the best innovative company in 2011. Joan Feixas is the chief executive officer of the company, and Llorenç Rafecas is its technical director.